Effect of Previsit AI-Generated Document Summaries on Consultation Time and Patient-Physician Communication - The AI-INFOCARE Randomized Controlled Trial.

NEJM AIOct 15, 2026 (epub)
Clinical ResearchNeurosurgery

Elida Benker-Hasani, Sven Richter, Clara Buszello et al.

✦ AI-curated · Sources linked

In 30 seconds

This single-center randomized controlled trial evaluated whether a quality-checked, AI-generated lay summary of medical findings before outpatient neurosurgical consultations affected communication and consultation time. Among 300 adults, the intervention group reported higher interaction quality than standard care (mean FAPI score, 4.42±0.51 vs. 4.25±0.54; difference, 0.17; 95% CI, 0.05 to 0.29) and had shorter median consultations (25 versus 33 minutes). Patient-rated autonomy support was also higher, while physicians rated their own autonomy support slightly lower. The authors call for further evaluation before routine adoption.

Key findings

  • Mean patient-reported FAPI scores were 4.42±0.51 versus 4.25±0.54; difference, 0.17 (95% CI, 0.05 to 0.29; P=0.005).
  • Median consultation time was 25 versus 33 minutes in the intervention and control groups, respectively (ratio of geometric means, 0.79; 95% CI, 0.70 to 0.88).
  • Patient-rated autonomy support was higher (difference, 0.14; 95% CI, 0.06 to 0.23), while physician-rated autonomy support was lower (difference, -0.12; cluster-robust 95% CI, -0.21 to -0.04).
  • Evidence for increased encounter difficulty was limited: difference, 0.09 (cluster-robust 95% CI, -0.03 to 0.21), compatible with no difference.

Why it matters

Patient-facing explanations of medical findings may help patients participate in consultations while reducing time spent in the encounter. The differing patient and physician ratings of autonomy support, and the uncertain signal for encounter difficulty, show that communication effects may not be uniform. The trial offers evidence about interaction outcomes, but does not establish effects on clinical outcomes or clinician workload.

What to keep in mind

The trial was conducted at a single center in an outpatient neurosurgical setting. Secondary-endpoint confidence intervals were unadjusted for multiplicity, and clinical outcomes and clinician workload were not established.

Source

Published in NEJM AI. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurosurgery

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.